STOCKHOLM, Oct. 24, 2019 /PRNewswire/ -- "We are now
regaining the exclusive, global rights to develop and commercialize
ADC-1013 and at the same time receive enough ADC-1013 substance to,
with or without a new partner, bring ADC-1013 into Phase II
clinical trials next year. In total, we now have three projects in
clinical development, and soon another one where the first patient
in Phase I will be dosed," commented CEO Per Norlén.
Significant events July-September
- Alligator regains the global rights for the CD40 antibody
ADC-1013 (mitazalimab) from Janssen.
- Alligator continued its work on the clinical development plan
for mitazalimab with the goal of starting a Phase II study in
2020.
- Antibody agreement was signed with Biotheus Inc. of
China, which obtained Chinese
rights to an antibody from the antibody library
ALLIGATOR-GOLD.
Events after the end of the period
- ATOR-1015: The Phase I clinical trial is progressing well with
seven dose levels evaluated for initial safety. Currently, doses of
100 mg, about 1.5 mg/kg, are given every two weeks.
- ALG.APV-527: Along with co-development partner Aptevo,
discussions are initiated with additional partners for the upcoming
clinical development of ALG.APV-527 and, therefore, the submission
of the application for permission to start clinical trial is
delayed. For Alligator, this ensures that resources are available
in order to bring the clinical portfolio forward with full
force.
Financial information
July-September 2019
- Net sales, SEK 4.3 million
(0.2)
- Total operating costs SEK -62.9
million (-40.6)
- Operating result, SEK -58.5
million (-39.9)
- Earnings per share before and after dilution, SEK -0.79 (-0.56)
- Cash flow for the period, SEK -46.8
million (-39.7)
- Cash, cash equivalents, incl securities, SEK 302.4 million (478.4)
January-September 2019
- Net sales, SEK 4.4 million
(1.4)
- Total operating costs SEK -160.2
million (-125.5)
- Operating result, SEK -155.2
million (-123.0)
- Earnings per share before and after dilution, SEK -2.11 (-1.67)
- Cash flow for the period, SEK -126.0
million (-70.0)
Read the complete report in the pdf below.
Conference call
All interested parties are invited to participate in a telephone
conference, which will include a presentation of the Interim
report. The event will be hosted by CEO Per
Norlén and the presentation will be held in
English.
When: 2:00 p.m. CEST Thursday 24, October 2019
Listen to the
presentation: https://tv.streamfabriken.com/alligator-bioscience-q3-2019
To participate in the telephone conference, please use the dial
in details shown below:
SE: +46856642707
UK: +443333009262
US: +18335268381
The conference call will be made available on the company's
website after the call.
This information is such information as Alligator Bioscience
AB (publ) is obliged to make public pursuant to the EU Market Abuse
Regulation. The information was submitted for publication, through
the agency of the contact persons set out above, at 8:00
a.m. CEST on October 24,
2019.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's growing pipeline includes five lead clinical and
preclinical drug candidates: ADC-1013 (mitazalimab), ATOR-1015,
ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator's shares are listed
on Nasdaq Stockholm (ATORX). The Company is headquartered in
Lund, Sweden, and has
approximately 55 employees. For more information, please visit
www.alligatorbioscience.com.
For further information, please contact:
Per Norlén, CEO, per.norlen@alligatorbioscience.com,
+46-46-540-82-00.
Per-Olof Schrewelius, CFO,
per-olof.schrewelius@alligatorbioscience.com, +46-46-540-82-03.
Cecilia Hofvander, Director IR &
Communications, cecilia.hofvander@alligatorbioscience.com,
+46-46-540-82-06.
Alligator Bioscience AB (publ) 556597-8201
Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden
Phone +46-46-540-82-00
www.alligatorbioscience.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-ab-interim-report-january-september-2019,c2939796
The following files are available for download:
https://mb.cision.com/Main/12681/2939796/1128507.pdf
|
Alligator Bioscience
AB Interim report January-September 2019
|